explore -WSS

explore

author：leisure time 2025-09-02 08:23:16 - browse：4725

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Flash flood warnings continue for parts of Missouri, Illinois

focus

WSS

Many breast cancer patients receive more radiation than needed

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

When waiting feels immoral: Empathy in the emergency department

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

How CRISPR works, explained in two minutes

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

focus

explore

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

H.R. 3 is the wrong path to lower drug costs

Virginia high school admissions case could be legal follow

Kansas bar where gunfire wounded 9 last month closes permanently

Alkermes shareholders re

The a glaring gap in research on serious mental illness and primary care

State Dept. review finds Biden bears some blame for Afghanistan failures

Paxlovid rebound happens. Why and to whom are still a mystery

Medicare details structure of new drug price negotiation program

Paxlovid rebound happens. Why and to whom are still a mystery

focus

Judge in Trump's classified documents case questions use of out

It was time to plan for my old age. If only I could stop crying

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Physicians aren't 'burning out.' They're suffering from moral injury

With heat waves through August, officials warn of health risks

Alnylam reports growth in sales of rare disease treatments

leisure time

Wikipedia

focus

focus